این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Blood and Cancer، جلد ۱۶، شماره ۴، صفحات ۵۶-۶۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Exploring the Basic Molecular Pathways: Metformin as a Potential Treatment Option for Pancreatic Cancer
چکیده انگلیسی مقاله
Background: Pancreatic cancer is one of the most aggressive and lethal malignancies, with limited treatment options and a poor prognosis. Recent research has highlighted the potential role of metformin, a widely used antidiabetic drug, in modulating cancer risk and progression. This review aims to explore the current evidence on the impact of metformin on pancreatic cancer outcomes and its potential mechanisms of action.
Materials and Methods: A comprehensive literature search was conducted using databases such as PubMed, Scopus, and Web of Science to identify studies investigating the relationship between metformin use and pancreatic cancer. Inclusion criteria encompassed clinical trials, cohort studies, and laboratory research published in the last two decades. Data extraction focused on patient outcomes, metformin dosage, study design, and proposed mechanisms of action.
Results: The review indicates that metformin use is associated with improved overall survival and reduced cancer incidence in patients with pancreatic cancer, particularly among those with concurrent diabetes. Mechanistic studies suggest that metformin exerts its anticancer effects through the inhibition of the mTOR pathway, reduction of insulin-like growth factors, and induction of autophagy. However, the results are heterogeneous, and several studies highlight the need for further clinical trials to establish causality and optimal therapeutic regimens.
Conclusion: While current evidence supports a potentially beneficial role of metformin in pancreatic cancer management, the findings are preliminary and require further validation through randomized controlled trials. The heterogeneity of the studies underscores the necessity for standardized protocols to assess the efficacy and safety of metformin as an adjunct therapy in pancreatic cancer treatment.
کلیدواژه‌های انگلیسی مقاله Metformin, Pancreatic Cancer, Molecular Pathways, Cancer Treatment, Cellular Energy, Metabolism
نویسندگان مقاله | Sepehr Ramezani
Babol University of Medical Science, Babol, Iran.


| Dariush Moslemi
Babol University of Medical Science, Babol, Iran.


| Faezeh Firuzpour
Babol University of Medical Science, Babol, Iran.


| Hamidreza Didar
Shahid Beheshti University of Medical Science, Tehran, Iran.


| Seyedamirmohammad Mazloumi
Babol University of Medical Science, Babol, Iran.


| Narjes rezaeiroushan
Azad University Sari Branch Faculty of Medicine, Sari, Iran.
نشانی اینترنتی http://ijbc.ir/browse.php?a_code=A-10-1228-1&slc_lang=en&sid=1
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده Adults Hematology & Oncology
نوع مقاله منتشر شده مقاله مروری
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات